1591 results about "Staphylococcus" patented technology

The invention discloses a polypeptide and application thereof in preparation of a medicine for preventing and / or treating cancers. The amino acid sequence of the polypeptide is shown as SEQ ID No. 1 or SEQ ID No. 2. The cancer is at least one of breast cancer, colorectal cancer, leukemia, esophageal cancer, pancreatic cancer, brain glioma, kidney cancer, skin cancer, osteosarcoma, ovarian cancer and prostate cancer. The invention designs and synthesizes the polypeptide of a targeted staphylococcus tumor protein compound SND1-MTDH containing a nuclease structural domain 1 (SND1 and a heteromucin (MTDH), finds that the polypeptide has excellent inhibitory activity on various different types of human cancer cells for the first time, and provides an optional scheme for broad-spectrum anti-cancer drugs. The polypeptide applied in the invention is simple in synthesis process and low in production cost.

The invention discloses a plant lactobacillus with a bacteriostatic effect and application of the plant lactobacillus. The lactobacillus plantarum is named as lactobacillus plantarum C07, the preservation number is CCTCC NO: M20242086, the preservation unit is China Center for Type Culture Collection, the preservation time is September 26, 2024, and the preservation address is Wuhan University, Wuhan University, No. 299, eight road, Wuchang District, Wuhan City, Hubei Province. The strain can produce lactic acid and indole-3-lactic acid at high yield, has a very strong antibacterial effect on multiple putrefying and pathogenic microorganisms such as staphylococcus aureus, escherichia coli, listeria monocytogenes, pseudomonas aeruginosa, salmonella and mould, and is a broad-spectrum antibacterial microorganism.

The invention discloses a polyrotaxane covalent organic framework material capable of regulating interlayer spacing through cyclodextrin and application of the polyrotaxane covalent organic framework material, and belongs to the technical field of biological medicine. The polyrotaalkylated covalent organic framework material is obtained by taking a cyclodextrin aromatic multi-amino inclusion compound and a (multi-aldehyde bipyridine) ruthenium (II) complex as structural units and carrying out copolymerization; the cyclodextrin aromatic polyamine inclusion compound is a beta-cyclodextrin p-phenylenediamine inclusion compound with a hydroxyl group or without a hydroxyl group; the (multi-aldehyde dipyridyl) ruthenium (II) complex is tris (4, 4 '-diformaldehyde-2, 2'-dipyridyl) ruthenium (II). The interlayer spacing of the polyrotaxane covalent organic framework material is greatly increased by utilizing a cavity of gamma-cyclodextrin, and meanwhile, the material has excellent photo-thermal and photodynamic activity, is positively charged, and can better adsorb negatively charged bacteria; and the hydrogel is good in biocompatibility and free of toxic and side effects, and has an excellent treatment effect on wounds infected with staphylococcus aureus.

The invention relates to the field of microorganisms, and discloses lactobacillus plantarum with an antibacterial effect and application of the lactobacillus plantarum, and the preservation number of the lactobacillus plantarum is CGMCC (China General Microbiological Culture Collection Center) No.33151. The strain provided by the invention has relatively strong cholate resistance, gastric acid resistance, acid production and H2O2 production capabilities, and has a relatively strong bacteriostatic effect on common pathogenic bacteria such as staphylococcus aureus, candida albicans, escherichia coli, salmonella and helicobacter pylori; the compound can inhibit the activity of urease, interfere helicobacter pylori colonization and the like to inhibit helicobacter pylori infection or reduce the symptoms of helicobacter pylori infection and reduce the disease degree of mice with colitis, can be used for preparing microbial preparations, and has the potential of preparing drugs for preventing and / or treating diseases caused by helicobacter pylori infection.

The invention relates to the field of microorganisms, in particular to a plant lactobacillus and application thereof in bacteriostasis. Specifically, the preservation number of the plant lactobacillus LP06 is CGMCC (China General Microbiological Culture Collection Center) No. 28412. The plant lactobacillus LP06 provided by the invention can be used for inhibiting the growth of debaryomyces hansenii, candida tropicalis and penicillium rochei, and also has an inhibiting effect on super bacteria acinetobacter baumannii, pseudomonas aeruginosa, klebsiella, escherichia coli, staphylococcus aureus and listeria monocytogenes. The plant lactobacillus LP06 provided by the invention has broad-spectrum bacteriostatic ability, and bacteriostatic powder prepared from the bacterium can be used as a biological preservative for corrosion prevention of dairy products such as yoghourt, cheese and the like and other foods.

The invention provides a Lactobacillus paracasei, which has a preservation number of CGMCC (China General Microbiological Culture Collection Center) No.32951. The Lactobacillus paracasei has a preservation number of CGMCC No.32951. The Lactobacillus paracasei has a preservation number of CGMCC No.32951. The lactobacillus paracasei ID001 provided by the invention has an inhibition effect on enteropathogenic bacteria such as salmonella, escherichia coli, staphylococcus aureus and the like. The probiotic preparation is obtained through fermentation and the dendrobium officinale extract, and the probiotic preparation has the immunoregulation effect through performance verification and screening.

The invention relates to the field of microorganisms, and discloses lactobacillus plantarum and application of the lactobacillus plantarum in preparation of a medicine for preventing and / or treating vaginitis, and the preservation number of the lactobacillus plantarum is CGMCC No.33152. The lactobacillus plantarum provided by the invention has a relatively strong bacteriostatic effect on common vaginal pathogenic bacteria such as Atortoria, staphylococcus aureus, Candida albicans, Escherichia coli and Gardneria, and also can reduce the infection degree of the pathogenic bacteria by inhibiting colonization and reproduction of the pathogenic bacteria; in addition, the proinflammatory factor level in sick vaginitis tissues is reduced, and the anti-inflammatory factor level is improved.

The invention belongs to the field of antibacterial peptides, and particularly relates to an antibacterial peptide with a broad-spectrum antibacterial effect, an antibacterial product and application. The antibacterial peptide is named as CAMP1111NC, and is obtained by performing N-terminal acetyl end capping and C-terminal amino end capping on polypeptide shown in SEQ ID NO: 1. The antibacterial peptide has remarkable antibacterial activity on a staphylococcus aureus standard strain ATCC12600, pseudomonas aeruginosa PAO1, klebsiella pneumoniae, an acinetobacter baumannii standard strain ATCC19606, methicillin-resistant staphylococcus aureus ATCC33591, methicillin-resistant and gentamicin-resistant staphylococcus aureus ATCC33592 and acinetobacter baumannii bio-53272 resistant to various antibiotics, and the antibacterial peptide can be used for preparing the antibacterial peptide. The limitation of the traditional antibacterial peptide is effectively overcome.

The invention discloses lactococcus gasseri C6a2 and application thereof. The preservation number of the lactococcus gasseri C6a2 is CGMCC (China General Microbiological Culture Collection Center) NO: 31024; the 16S rRNA (ribosomal Ribonucleic Acid) gene sequence of the lactococcus gasseri C6a2 is as shown in SEQ ID NO: 1. The bacterial strain is a macrobrachium rosenbergii intestinal absolute dominant bacterium, has a typical probiotic function, is high in growth speed and activity, can quickly enter a logarithmic phase, has relatively high acid production and acid resistance, can secrete lipase, has relatively high bacteriostatic activity on staphylococcus aureus, aeromonas hydrophila and aeromonas veronii, and can be used for preparing the macrobrachium rosenbergii. The bacterium can be used for preparing a special probiotic preparation for macrobrachium rosenbergii, so that the sustainable development of the macrobrachium rosenbergii industry in China is promoted.

The invention relates to the technical field of antibacterial peptide application, in particular to an antibacterial peptide for inhibiting drug-resistant staphylococcus aureus and application of the antibacterial peptide. The antibacterial peptide is obtained by performing N-terminal acetylation modification and C-terminal amidation modification on polypeptide as shown in SEQ ID NO.1. The invention further discloses a preparation method of the antibacterial peptide. The antibacterial peptide provided by the invention is a novel cationic antibacterial peptide, the minimum inhibitory concentrations of the antibacterial peptide to pathogenic bacteria staphylococcus aureus ATCC12600 and staphylococcus aureus ATCC33591 are respectively 4 [mu] g / mL and 32 [mu] g / mL, the biological safety is extremely high, and due to the characteristics, the antibacterial peptide shows extremely high medical drug antibacterial value, and can be used for preparing the antibacterial peptide. Alternative medicinal resources are provided for clinically resisting the two human pathogenic bacteria in the future.

The invention provides lactobacillus crispatus, which is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms on February 7, 2023, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No. 26503. The bacillus subtilis can play a relatively strong role in inhibiting pathogenic bacteria such as gardnerella vaginalis, escherichia coli and staphylococcus aureus at the same time, and also has a certain role in inhibiting candida albicans, two-way proteurella and Atortoria vaginalis. Therefore, the lactobacillus crispatus has the potential of maintaining the environment in the vagina to be faintly acid and improving the mucosal immunity and infection resistance of a host, and can be used for preventing and treating vaginal infection and inflammation, and maintaining, improving or recovering the steady state of the environment in the vagina.

The invention provides a nucleic acid composition for respiratory tract pathogen detection and application thereof, and relates to the technical field of biology. The invention provides a nucleic acid detection composition which has high specificity and can be used for detecting various respiratory pathogens. The composition can be used for detecting influenza B virus, influenza A virus H1N1, influenza A virus H3N2, novel coronavirus N gene, novel coronavirus O gene, respiratory syncytial virus, I-type parainfluenza virus, II-type parainfluenza virus, III-type parainfluenza virus, IV-type parainfluenza virus, rhinovirus, adenovirus, haemophilus influenzae, and the like. The kit has 15 pathogens including streptococcus pneumoniae and staphylococcus aureus, the lower detection limit can be as low as 20 copies / reaction, and the kit plays an important role in rapid detection of respiratory tract pathogens.

The invention discloses an antibacterial peptide and application thereof, and belongs to the technical field of biology. The antibacterial peptide with an inhibition effect on various clinically common pathogenic microorganisms is obtained, and the antibacterial peptide comprises gram-negative bacteria such as escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, acinetobacter baumannii, vibrio parahaemolyticus, salmonella gallinarum, salmonella typhimurium and enterobacter sakazakii, and gram-positive bacteria. The antibacterial peptide provided by the invention can be used as an antibacterial peptide, such as staphylococcus aureus, listeria monocytogenes and bacillus cereus, and the antibacterial peptide provided by the invention is novel in structure and easy to prepare.

The invention discloses staphylococcus vorus X9 with an antibiotic degradation function and application of the staphylococcus vorus X9 in antibiotic degradation, and belongs to the technical field of microorganisms. The staphylococcus vorus X9 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.32162. The strain has an excellent degradation effect on erythromycin and oxytetracycline, so that the strain has application value and prospect in the field of antibiotic degradation. Therefore, the compound can be prepared into a microbial agent which is used for purifying an environment polluted by antibiotics.

A breast milk-derived Limosilactobacillus fermentum MSJK0025 capable of improving the intestinal flora condition and the use thereof. The breast milk-derived Limosilactobacillus fermentum MSJK0025 is deposited in the China General Microbiological Culture Collection Center with a deposit number of CGMCC No. 26426. The breast milk-derived Limosilactobacillus fermentum is a new strain isolated from breast milk of healthy puerperae, and is referred to as Limosilactobacillus fermentum MSJK0025. The strain has a good antibiotic sensitivity and stable inheritance of traits, has a good tolerance to acid, bile salts and artificial gastric / intestinal fluid, and has a fast growth rate and good safety. Furthermore, the strain has a strong intestinal colonization capability and can effectively inhibit intestinal pathogenic bacteria such as Escherichia coli, Staphylococcus aureus, Salmonella typhimurium and Candida albicans, but has no inhibitory effects on intestinal probiotics such as Lactobacillus and Bifidobacterium.

The invention relates to a bifidobacterium animalis subsp. Lactis YYSJ001 with a blood sugar reducing effect and application of the bifidobacterium animalis subsp. Lactis YYSJ001. The classification name of the strain is bifidobacterium animalis subsp. Lactis, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.33471. The invention further relates to a preparation method of the bifidobacterium animalis subsp. Lactis YYSJ001. The bacterial strain has good artificial gastric juice resistance, artificial intestinal juice resistance and intestinal tract adhesion ability, has an inhibition effect on numerous pathogenic bacteria such as escherichia coli, staphylococcus aureus, salmonella, klebsiella pneumoniae and quail chicken enterococcus, and can stimulate intestinal cells to generate glucagon-like peptide-1, so that the bacterial strain can be applied to preparation of various pathogenic bacteria. Diseases of diabetic mice can be effectively improved, and the compound can be used for preparing products for preventing and treating diabetes or assisting in reducing blood sugar.

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide and application thereof. The amino acid sequence of the antibacterial peptide is shown as SEQ ID NO: 1, the number of amino acids is small, the synthesis cost is low, the antibacterial peptide has high antibacterial activity on gram-negative bacteria and gram-positive bacteria, the minimum inhibitory concentration of the antibacterial peptide on acinetobacter baumannii, escherichia coli, pseudomonas aeruginosa and staphylococcus aureus is 4.68-37.5 mu g / mL, and the antibacterial peptide has the advantages of broad-spectrum antibacterial property, good stability and good application prospect. No obvious cytotoxicity and hemolysis effect exist; moreover, end-to-end amido bond cyclization is carried out, so that the antibacterial activity is further enhanced, the antibacterial effect on acinetobacter baumannii, escherichia coli, pseudomonas aeruginosa and staphylococcus aureus is enhanced by 2-4 times, and the minimum inhibitory concentration is reduced to 2.34-9.38 mu g / mL; after the end-to-end amido bonds are cyclized, the plasma stability and safety of the antibacterial peptide are further improved, and the cytotoxicity and hemolysis are reduced.

The invention discloses staphylococcus NHY-25 capable of producing enzyme and aroma, which is preserved in Guangdong Microbial Culture Collection Center on May 26, 2025, and the preservation number is GDMMC NO: 66396. When the strain is applied to yeast strengthening, the enzyme activity in high-temperature yeast can be improved, for example, the activity of protease, saccharifying power, fermenting power and liquefying power of yeast can be improved. Through detection of volatile compounds in the strengthened Daqu and the unstrengthened Daqu, it is found that the strain enables the variety and content of the volatile compounds in the strengthened Daqu to be improved. The strain enables the sauce flavor of high-temperature yeast to be more prominent, can be applied to yeast strengthening, and provides a new thought for improving the quality of yeast.

The invention provides copper-loaded duck-origin lactobacillus plantarum with high antibacterial peptide yield and application of the copper-loaded duck-origin lactobacillus plantarum. The preservation number of the provided copper-loaded duck-origin lactobacillus plantarum is CGMCC (China General Microbiological Culture Collection Center) NO.32835. The domesticated and bred duck-origin lactobacillus plantarum with high antibacterial peptide yield can tolerate high-concentration copper ions, the domesticated and bred lactobacillus plantarum can stably grow, and the contents of antibacterial peptide, extracellular protein, lipase, amylase, lactic acid, acetic acid and the like in the domesticated and bred lactobacillus plantarum strain are increased; and the amino acid composition is changed. The strain can convert inorganic copper into organic copper, the utilization rate of copper is increased, and growth and development of organisms are promoted. Moreover, small peptides and extracellular proteins in metabiotics generated after fermentation have the effect of effectively inhibiting harmful bacteria such as riemerella anatipestifer, escherichia coli, salmonella and staphylococcus of poultry, and are beneficial to eliminating intestinal inflammatory factors, maintaining intestinal health and improving the feed utilization rate.

The invention discloses lactobacillus mucilaginosus and application thereof in fermentation of sporoderm-broken ganoderma lucidum spore powder. The preservation number of the lactobacillus mucilaginosus is CGMCC (China General Microbiological Culture Collection Center) No.31453. The strain is separated and screened from vaginal secretions of healthy women at the childbearing age, is not hemolyzed, is sensitive to various common antibiotics and has strong lactic acid production capacity, and fermented supernate of the strain has strong growth inhibition capacity on escherichia coli, pseudomonas aeruginosa, staphylococcus aureus, salmonella typhimurium, shigella dysenteriae and gardnerella vaginalis and can be used for producing lactic acid. The compound has strong adhesion ability, growth inhibition ability and apoptosis promoting effect on human cervical cancer cells. When the strain is used for fermenting wall-broken ganoderma lucidum spore powder, the content of bioactive substances such as amino acids and derivatives thereof, fatty acids and steroids in fermentation liquor can be greatly increased, the strain has an obvious anti-inflammatory effect on DSS-induced mouse colitis, and the inflammatory factor level is remarkably reduced. The strain not only has significant application value in functional food and biological agents, but also opens up a new way for further development of ganoderma spores.

The invention relates to Penicillium decumbens C01 and application of the Penicillium decumbens C01, and belongs to the technical field of microorganisms. The penicillium decumbens C01 disclosed by the invention is preserved in the Guangdong Microbial Culture Collection Center, and the preservation number of the penicillium decumbens C01 is GDMCC NO.66456. The strain is obtained by separating, purifying and screening soil samples collected from botanical gardens in South China of Guangzhou; tests show that the bacteriostatic active substance generated by fermentation of the strain has a good bacteriostatic effect on staphylococcus epidermidis, staphylococcus aureus, escherichia coli, propionibacterium acnes, candida albicans and pseudomonas aeruginosa, and the bacteriostatic active substance has the characteristic of high temperature resistance and excellent preservative effect; the antibacterial preservative can be used as an antibacterial preservative raw material, is applied to the fields of food, health care products or daily chemical products and the like, and has wide application prospects and important conversion research values.

The invention belongs to the technical field of biology, and provides enterococcus faecalis, the preservation number of which is CGMCC (China General Microbiological Culture Collection Center) No.29087. The enterococcus faecalis is characterized in that the enterococcus faecalis can secrete bacteriocin for inhibiting vibrio parahaemolyticus, staphylococcus aureus and escherichia coli. The invention also provides the enterococcus faecalis and application thereof in an aquatic product fermented feed and a laying hen premix, and the enterococcus faecalis can effectively improve the utilization rate of the feed and the growth and production performance of animals.

The invention belongs to the technical field of antibiosis and wound healing promotion, and relates to double-response (near-infrared light and hydrogen peroxide double-response photo-thermal / carbon monoxide therapy) antibacterial hydrogel as well as preparation and application thereof. The invention relates to a double-response antibacterial hydrogel. The antibacterial hydrogel is prepared from the following components: drug-loaded nano particles and a hydrogel matrix. The drug-loaded nano particles are prepared by loading dimanganese decacarbonyl (MnCO) into cavities of hollow mesoporous copper sulphide nano particles (HMCuS NPs) and coating the surfaces of the particles with a polydopamine layer (PDA). According to the invention, CO / PTT synergistic treatment of bacterial infected wounds is realized, and the antibacterial effect is significantly improved. An in-vitro antibacterial experiment result shows that the antibacterial hydrogel shows extremely strong inhibition capability on escherichia coli and staphylococcus aureus, and the problem of drug resistance caused by a bacterial biofilm is effectively solved.

The invention relates to application of ten antibacterial peptides in the antimicrobial field. The ten antibacterial peptides have strong antibacterial activity on multi-drug-resistant bacteria, including but not limited to gram-negative bacteria such as escherichia coli, pseudomonas aeruginosa, acinetobacter baumannii, klebsiella pneumoniae and the like, and gram-positive bacteria such as staphylococcus aureus, enterococcus faecalis and the like. Activity research proves that any one of the ten antibacterial peptides has a remarkable effect of inhibiting, killing or preventing microbial infection. Due to the strong antibacterial property of any antibacterial peptide, the antibacterial peptide has wide application potential in the aspects of preparing antibacterial drugs, preservatives, antibacterial coatings, antibacterial fibers, antibacterial packaging materials and the like. Due to the unique property of the antibacterial peptide in the aspect of antibacterial performance, a new direction is provided for the development of efficient and reliable antibacterial agents and antibacterial technologies and products in multiple fields.

The invention relates to the technical field of antibacterial peptides, and discloses a novel Rhodospirillales antibacterial peptide and application thereof, and the amino acid sequence of the antibacterial peptide is as shown in SEQ ID NO: 1. The antibacterial peptide obtained by the invention has a relatively good antibacterial effect on staphylococcus aureus.

The invention discloses a Brucella with antibacterial activity and application of the Brucella. The invention discloses Burkholderia sp.HNIV0701, and the preservation number of the Burkholderia sp.HNIV0701 is GDMCC No: 66007. The Burkholderia sp.HNIV0701 disclosed by the invention has a stable, efficient and broad-spectrum antibacterial property, has an inhibition effect on a plurality of plant pathogenic bacteria such as Botryosphaeria dothidea, Phytophthora nicotianae, Fusarium solani, Alternaria alternata, Thanatepora cucurbitae, Ralstonia solanacearum and the like, and also can be used for inhibiting Staphylococcus aureus and / or Listeria monocytogenes, so that the Burkholderia sp.HNIV0701 can be used for inhibiting a plurality of plant pathogenic bacteria such as the Botryosphaeria dothidea, the Phytophthora nicotianae, the Fusarium solanum, the Alternaria solanacearum and the like. The Brucella HNIV0701 can hydrolyze organic phosphorus and can be used for soil improvement. The Brucella HNIV0701 has nitrogen fixation capability and has the potential of promoting plant growth.

The invention discloses a core-shell structure nano calcium carbonate antibacterial composite powder and a preparation method thereof.The preparation method comprises the steps that firstly, the surface of nano calcium carbonate is coated with a layer of amorphous TiO2 to form a CaCO3 at-TiO2 core-shell structure, then CaCO3 at-TiO2 reacts with 3-isocyanate propyl trimethoxy silane to generate a Ti-O-Si chemical bond on the surface of the CaCO3 at-TiO2 core-shell structure, and the core-shell structure nano calcium carbonate antibacterial composite powder is obtained; finally, Ag < + > is adsorbed to the surface of CaCO3 (at) TiO2 under the electrostatic action of Si-OH and is reduced into nano silver under the action of sodium citrate, and the CaCO3 (at) TiO2 (at) Ag core-shell structure antibacterial composite powder which is uniform in coating and good in dispersity is formed. The core-shell structure antibacterial composite powder disclosed by the invention shows excellent antibacterial performance in an antibacterial test on escherichia coli and staphylococcus aureus. The method provided by the invention provides a new research thought for preparation of a nano calcium carbonate core-shell structure and a nano silver antibacterial agent.

The invention belongs to the technical field of antibacterial active microorganisms, and particularly relates to a strain of diffusion carbon pad bacteria LUCF 4343-3, a bacterial agent and application of the bacterial agent in preparation of an antibacterial preparation. According to the invention, an endophytic fungus strain with remarkable antibacterial potential is successfully separated from Parmotrema, and the endophytic fungus strain is identified as diffusion carbon pad fungus LUCF 4343-3. Experiments show that an ethyl acetate extract of the strain shows a good inhibition effect on various clinical common pathogenic bacteria, including gram-positive bacteria (staphylococcus aureus and enterococcus faecalis), gram-negative bacteria (pseudomonas aeruginosa), fungi (candida albicans and candida glabrata) and the like; the discovery provides an important basis for the application of the strain in the development of novel broad-spectrum antibacterial drugs.

The invention relates to the field of biological medicine, in particular to application of cepharanthine in preparation of a pathogenic bacterium biofilm scavenger, an anti-pathogenic bacterium medicine and a medical equipment coating material. Staphylococcus aureus is taken as a pathogenic bacterium, the removal effect of cepharanthine on a biological membrane is detected through biological membrane formation and destruction experiments, and the curative effect of cepharanthine on infection is evaluated by constructing a staphylococcus aureus infected mouse model. The result shows that the cepharanthine inhibits the formation of the staphylococcus aureus biological membrane and destroys the formed biological membrane; animal experiments show that the cepharanthine improves the survival rate of mice infected with the staphylococcus aureus, reduces the colonial colonization number of lungs of the infected mice, and improves the elimination capability of a host to pathogenic bacteria. Therefore, the invention has important significance in the aspects of research and development of targeted biological membranes and drugs for resisting drug-resistant bacterium infection, improvement of the curative effect of antibiotics, prolonging of the service life of the drugs and the like.

The invention discloses an antibacterial peptide fragment intercepted from chitinase IDGF4 protein and application of the antibacterial peptide fragment in preparation of antibacterial drugs. According to the invention, short peptide fragments in chitinase IDGF4 protein are screened, three candidate peptides are obtained through chemical synthesis, the antibacterial performance of the candidate peptides is systematically evaluated, and the evaluation result shows that the peptide fragment with the amino acid sequence as shown in SEQ ID No.2 can effectively inhibit the growth of salmonella and staphylococcus aureus under the concentration of 1mg / mL; the antibacterial effect of the compound is confirmed in inhibition zone experiments, enzyme-labeled turbidimetry and growth curve monitoring, and the compound shows stable and remarkable antibacterial activity and can be used as a novel antibacterial molecule; the invention provides a new candidate sequence for developing the antibacterial peptide with high efficiency and low drug resistance risk, and has application potential in the aspect of preparing clinical antibacterial drugs.